➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
Baxter
Mallinckrodt
Express Scripts

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Vaborbactam

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Vaborbactam?

Vaborbactam is an investigational drug.

There have been 5 clinical trials for Vaborbactam. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2014.

The most common disease conditions in clinical trials are Infection, Pyelonephritis, and Pneumonia, Bacterial. The leading clinical trial sponsors are Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), Department of Health and Human Services, and Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.).

There are six US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for Vaborbactam
TitleSponsorPhase
A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial PneumoniaMelinta Therapeutics, Inc.Phase 3
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy VolunteersBiomedical Advanced Research and Development AuthorityPhase 1
Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy VolunteersRempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)Phase 1

See all Vaborbactam clinical trials

Clinical Trial Summary for Vaborbactam

Top disease conditions for Vaborbactam
Top clinical trial sponsors for Vaborbactam

See all Vaborbactam clinical trials

US Patents for Vaborbactam

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vaborbactam   Start Trial Deuterated O-sulfated beta lactam hydroxamic acids and deuterated N-sulfated beta lactams ARIXA PHARMACEUTICALS, INC. (Palo Alto, CA)   Start Trial
Vaborbactam   Start Trial Metallo-beta-lactamase inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Vaborbactam   Start Trial Metallo-.beta.-lactamase inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Vaborbactam   Start Trial Cyclic boronic acid ester derivatives and therapeutic uses thereof Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Vaborbactam   Start Trial Cyclic boronic acid ester derivatives and therapeutic uses thereof Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
Vaborbactam   Start Trial Cyclic boronic acid ester derivatives and therapeutic uses thereof Rempex Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vaborbactam

Drugname Country Document Number Estimated Expiration Related US Patent
Vaborbactam World Intellectual Property Organization (WIPO) 2017180794 2036-04-13   Start Trial
Vaborbactam Argentina 105122 2035-06-26   Start Trial
Vaborbactam Australia 2016281710 2035-06-26   Start Trial
Vaborbactam Brazil 112017027719 2035-06-26   Start Trial
Vaborbactam Canada 2990234 2035-06-26   Start Trial
Vaborbactam Chile 2017003325 2035-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Merck
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.